ICHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ichor Holdings Ltd (ICHR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price declines, the stock has strong analyst support, positive growth catalysts, and favorable technical indicators. The company's guidance for 2026 and 2027 suggests significant growth potential, and the options data reflects bullish sentiment. This aligns well with the user's investment profile and goals.
The technical indicators are mixed but lean slightly bullish. The MACD is above 0 and positively contracting, indicating potential upward momentum. The RSI is neutral at 48.268, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at $44.705, and resistance is at $53.72, suggesting the current price of $46.45 is near support levels, offering a potential entry point.
Analysts have raised price targets significantly, with most ratings being 'Buy' and targets ranging from $48 to $
The company has issued strong guidance for Q1 and FY26, indicating recovery and growth in its end markets.
Management is shifting production capacity to higher-profitability regions, which could enhance margins.
Options data reflects bullish sentiment, supporting potential price appreciation.
The stock experienced a significant 10.51% drop in regular market trading, which may indicate short-term volatility.
Financials show a YoY revenue decline of -4.15% and a gross margin drop of -18.98%, reflecting some operational challenges.
No recent news or major event-driven catalysts to drive immediate price action.
In Q4 2025, revenue dropped to $223.6M (-4.15% YoY), but net income improved significantly to -$15.96M (+304.79% YoY), and EPS increased to -0.46 (+283.33% YoY). Gross margin declined to 8.45% (-18.98% YoY). While revenue and gross margin faced challenges, the company's profitability metrics showed notable improvement, indicating progress in operational efficiency.
Analysts are overwhelmingly positive on ICHR, with multiple upgrades and price target increases following strong Q4 results and guidance. Price targets range from $30 to $55, with most firms maintaining a 'Buy' rating. Analysts highlight the company's leverage to high-growth segments, improved credibility under new leadership, and strong demand recovery in its markets.
